Modality
Radioligand
MOA
BCMA ADC
Target
CD38
Pathway
RNA Splicing
Breast Ca
Development Pipeline
Preclinical
~May 2021
→ ~Aug 2022
Phase 1
~Nov 2022
→ ~Feb 2024
Phase 2
~May 2024
→ ~Aug 2025
Phase 3
Nov 2025
→ Feb 2028
Phase 3Current
NCT03055014
226 pts·Breast Ca
2025-11→2028-02·Terminated
226 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-02-231.9y awayPh3 Readout· Breast Ca
Trial Timeline
2026Q2Q3Q42027Q2Q3Q42028
P3
Termina…
Catalysts
Ph3 Readout
2028-02-23 · 1.9y away
Breast Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03055014 | Phase 3 | Breast Ca | Terminated | 226 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A |